重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识(2012版)

[1] 临床应用重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中专家共识 [J]. 中华内科杂志, 2006, (07) : 613 - 614

[2] Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis[J] . Joanna M Wardlaw,Veronica Murray,Eivind Berge,Gregory del Zoppo,Peter Sandercock,Richard L Lindley,Geoff Cohen.The Lancet . 2012 (9834)

[3] Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score[J] . Michael Mazya,José A. Egido,Gary A. Ford,Kennedy R. Lees,Robert Mikulik,Danilo Toni,Nils Wahlgren,Niaz Ahmed.Stroke . 2012 (6)

[4] Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator: Findings From Get With The Guidelines–Stroke[J] . Eric E. Smith,Gregg C. Fonarow,Mathew J. Reeves,Margueritte Cox,DaiWai M. Olson,Adrian F. Hernandez,Lee H. Schwamm.Stroke . 2011 (11)

[5] Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR)[J] . Yilong Wang,Xiaoling Liao,Xingquan Zhao,David Z. Wang,Chunxue Wang,Mai N. Nguyen-Huynh,Yong Zhou,Liping Liu,Xianwei Wang,Gaifen Liu,Hao Li,Yongjun Wang.Stroke . 2011 (6)

[6] Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes[J] . Gregg C. Fonarow,Eric E. Smith,Jeffrey L. Saver,Mathew J. Reeves,Deepak L. Bhatt,Maria V. Grau-Sepulveda,DaiWai M. Olson,Adrian F. Hernandez,Eric D. Peterson,Lee H. Schwamm.Circulation . 2011 (7)

[7] Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator [J]. STROKE, 2011, 42 (04) : 1041 - 1045

[8] Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA)[J] . Nishant Kumar Mishra,Hans-Christoph Diener,Patrick D. Lyden,Erich Bluhmki,Kennedy R. Lees.Stroke . 2010 (12)

[9] Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)[J] . Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi.Stroke . 2010 (9)

[10] Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J] . Kennedy R Lees,Erich Bluhmki,Rüdiger von Kummer,Thomas G Brott,Danilo Toni,James C Grotta,Gregory W Albers,Markku Kaste,John R Marler,Scott A Hamilton,Barbara C Tilley,Stephen M Davis,Geoffrey A Donnan,Werner Hacke.The Lancet . 2010 (9727)

[1] 临床应用重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中专家共识 [J]. 中华内科杂志, 2006, (07) : 613 - 614

[2] Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis[J] . Joanna M Wardlaw,Veronica Murray,Eivind Berge,Gregory del Zoppo,Peter Sandercock,Richard L Lindley,Geoff Cohen.The Lancet . 2012 (9834)

[3] Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score[J] . Michael Mazya,José A. Egido,Gary A. Ford,Kennedy R. Lees,Robert Mikulik,Danilo Toni,Nils Wahlgren,Niaz Ahmed.Stroke . 2012 (6)

[4] Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator: Findings From Get With The Guidelines–Stroke[J] . Eric E. Smith,Gregg C. Fonarow,Mathew J. Reeves,Margueritte Cox,DaiWai M. Olson,Adrian F. Hernandez,Lee H. Schwamm.Stroke . 2011 (11)

[5] Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR)[J] . Yilong Wang,Xiaoling Liao,Xingquan Zhao,David Z. Wang,Chunxue Wang,Mai N. Nguyen-Huynh,Yong Zhou,Liping Liu,Xianwei Wang,Gaifen Liu,Hao Li,Yongjun Wang.Stroke . 2011 (6)

[6] Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes[J] . Gregg C. Fonarow,Eric E. Smith,Jeffrey L. Saver,Mathew J. Reeves,Deepak L. Bhatt,Maria V. Grau-Sepulveda,DaiWai M. Olson,Adrian F. Hernandez,Eric D. Peterson,Lee H. Schwamm.Circulation . 2011 (7)

[7] Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator [J]. STROKE, 2011, 42 (04) : 1041 - 1045

[8] Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA)[J] . Nishant Kumar Mishra,Hans-Christoph Diener,Patrick D. Lyden,Erich Bluhmki,Kennedy R. Lees.Stroke . 2010 (12)

[9] Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)[J] . Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi.Stroke . 2010 (9)

[10] Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J] . Kennedy R Lees,Erich Bluhmki,Rüdiger von Kummer,Thomas G Brott,Danilo Toni,James C Grotta,Gregory W Albers,Markku Kaste,John R Marler,Scott A Hamilton,Barbara C Tilley,Stephen M Davis,Geoffrey A Donnan,Werner Hacke.The Lancet . 2010 (9727)